Evidence map›Paper›PMID 37104389›Full record

ArticlePloS one2023

Mutability of druggable kinases and pro-inflammatory cytokines by their proximity to telomeres and A+T content.

Ian McKnight, Regan Raines, Hunter White, Nasim Nosoudi, Chan Lee, Peter H U Lee, Joon W Shim

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Frontiers in genetics · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ian McKnightDepartment of Biomedical Engineering, College of Engineering and Computer Sciences, Marshall University, Huntington, West Virginia, United States of America.
Regan RainesDepartment of Biomedical Engineering, College of Engineering and Computer Sciences, Marshall University, Huntington, West Virginia, United States of America.
Hunter WhiteDepartment of Biomedical Engineering, College of Engineering and Computer Sciences, Marshall University, Huntington, West Virginia, United States of America.
Nasim NosoudiDepartment of Biomedical Engineering, College of Engineering and Computer Sciences, Marshall University, Huntington, West Virginia, United States of America.
Chan LeeDepartment of Anesthesia, Indiana University Health Arnett Hospital, Lafayette, Indiana, United States of America.
Peter H U LeeDepartment of Cardiothoracic Surgery, Southcoast Health, Fall River, Massachusetts, United States of America.
Joon W ShimDepartment of Biomedical Engineering, College of Engineering and Computer Sciences, Marshall University, Huntington, West Virginia, United States of America.ORCID 0000-0002-5490-684X
Marshall University · USBrown University · USIndiana University Health · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI Travis Salisbury · 2012 to 2026
$61.1M
Regulation of Tight Junction Molecular Composition by Na/K-ATPaseP20GM121299 · NIGMS · MARSHALL UNIVERSITY · PI HAYNES, JENNIFER · 2018 to 2022
$10.6M
NIGMS NIH HHS P20 GM103434NIGMS NIH HHS P20 GM121299NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

Mutations of protein kinases and cytokines are common and can cause cancer and other diseases. However, our understanding of the mutability in these genes remains rudimentary. Therefore, given previously known factors which are associated with high mutation rates, we analyzed how many genes encoding druggable kinases match (i) proximity to telomeres or (ii) high A+T content. We extracted this genomic information using the National Institute of Health Genome Data Viewer. First, among 129 druggable human kinase genes studied, 106 genes satisfied either factors (i) or (ii), resulting in an 82% match. Moreover, a similar 85% match rate was found in 73 genes encoding pro-inflammatory cytokines of multisystem inflammatory syndrome in children. Based on these promising matching rates, we further compared these two factors utilizing 20 de novo mutations of mice exposed to space-like ionizing radiation, in order to determine if these seemingly random mutations were similarly predictable with this strategy. However, only 10 of these 20 murine genetic loci met (i) or (ii), leading to only a 50% match. When compared with the mechanisms of top-selling FDA approved drugs, this data suggests that matching rate analysis on druggable targets is feasible to systematically prioritize the relative mutability-and therefore therapeutic potential-of the novel candidates.

Indexed as

CytokinesNeoplasmsAnimalsChildGenomicsHumansMiceMutationTelomereCytokines

Identifiers

PMID37104389
PMCPMC10138820
OpenAlexW4367173746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.